Crown Bioscience Invests in Commercial Leadership
20.7.2021 15:30:00 EEST | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company, today announces the appointment of Alex Slater as Vice President of Business Development, North America and Europe. In this role, Mr Slater will be responsible for the continued growth within the Company’s existing services portfolio and for setting the foundation for the expansion of new services.
The investment in additional leadership within CrownBio’s commercial and strategic development division reflects the increasing breadth and scientific depth of the company's offerings, and an appreciation of the need for tailored solutions at both an account and territory level. The new position will complement recent expansions in CrownBio’s Marketing, Product Management and Scientific Engagement departments, and is part of the company’s broader commitment to ensure that their customers' experience is industry-leading.
Commenting on the appointment, Mike Prosser, Senior Vice President, Commercial and Strategic Development, said, “I am delighted to welcome Alex to the team, and to fill another crucial role for the company, during an exciting phase of CrownBio’s growth. Alex’s extensive leadership experience in the CRO industry, encompassing multiple phases of drug discovery and development, will be invaluable to us as we evolve our teams in line with market opportunity.”
Mr. Slater joins CrownBio from Biocellvia, where he was VP of the business development function. In previous roles, he has served as Global VP for Business Development at Eurofins and held multiple sales leadership positions at Covance/LabCorp.
“During my interview process I was impressed by the strength of the leadership team at CrownBio, their commitment to innovation and the value they place in their customers’ experience,” commented Alex. “Further, the business development team already in place at CrownBio is highly motivated and professional and in my capacity as VP of Business Development I look forward to working with them to accelerate the organization’s future expansion.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Find out more at: http://www.CrownBio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005688/en/
Contact information
Media Enquiries:
Louise Stenson
Crown Bioscience
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 16:26:00 EET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at an adjusted PBR of 0.40x, representing a severe 60% discount to its Comprehensive Equity under IFRS17. Align Partners identifies inefficient capital allocation and a lack of independent governance oversight as primary drivers of this persistent undervaluation. The letter notes that DBI’s Return on Required Capital (ROR) of 21.2% significantly lags behind domestic and global peers, reflecting a historical focus on top-line growth over risk-adjusted profitability. This is exacerbated by a passive payout policy and
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 14:00:00 EET | Press release
Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/en/ “You can now potentially study intracellular target engagement for any protein in live cells,” says M
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 14:00:00 EET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 12:37:00 EET | Press release
Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming from outside Hong Kong. The HKTDC presents the world’s largest one-s
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 12:30:00 EET | Press release
FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integrate FX Spot+ and EBS Market liquidity into their existing FlexFX workflows, accelerating time to market and r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom